FGFR1 Signaling Facilitates Obesity-Driven Pulmonary Outgrowth in Metastatic Breast Cancer

被引:4
|
作者
Cotul, Eylem Kulkoyluoglu [1 ]
Safdar, Muhammad Hassan [1 ]
Paez, Sebastian Juan [1 ]
Kulkarni, Aneesha [1 ]
Ayers, Mitchell G. [1 ]
Lin, Hang [1 ]
Xianyu, Zilin [1 ]
Teegarden, Dorothy [2 ,3 ]
Hursting, Stephen D. [4 ,5 ,6 ]
Wendt, Michael K. [1 ,2 ,7 ]
机构
[1] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN USA
[2] Purdue Univ Inst Canc Res, Inst Canc Res, W Lafayette, IN USA
[3] Purdue Univ, Dept Nutr Sci, W Lafayette, IN USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[5] Univ N Carolina, Nutr Res Inst, Kannapolis, NC USA
[6] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA
[7] Purdue Univ, Dept Med Chem & Mol Pharmacol, 201 S Univ St, W Lafayette, IN 47907 USA
关键词
GROWTH-FACTOR RECEPTOR; HEPARAN-SULFATE; BINDING; EXPRESSION; KINETICS;
D O I
10.1158/1541-7786.MCR-23-0955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Survival of dormant, disseminated breast cancer cells contributes to tumor relapse and metastasis. Women with a body mass index greater than 35 have an increased risk of developing metastatic recurrence. Herein, we investigated the effect of diet-induced obesity (DIO) on primary tumor growth and metastatic progression using both metastatic and systemically dormant mouse models of breast cancer. This approach led to increased PT growth and pulmonary metastasis. We developed a novel protocol to induce obesity in Balb/c mice by combining dietary and hormonal interventions with a thermoneutral housing strategy. In contrast to standard housing conditions, ovariectomized Balb/c mice fed a high-fat diet under thermoneutral conditions became obese over a period of 10 weeks, resulting in a 250% gain in fat mass. Obese mice injected with the D2.OR model developed macroscopic pulmonary nodules compared with the dormant phenotype of these cells in mice fed a control diet. Analysis of the serum from obese Balb/c mice revealed increased levels of FGF2 as compared with lean mice. We demonstrate that serum from obese animals, exogenous FGF stimulation, or constitutive stimulation through autocrine and paracrine FGF2 is sufficient to break dormancy and drive pulmonary outgrowth. Blockade of FGFR signaling or specific depletion of FGFR1 prevented obesity-associated outgrowth of the D2.OR model.Implications: Overall, this study developed a novel DIO model that allowed for demonstration of FGF2:FGFR1 signaling as a key molecular mechanism connecting obesity to breakage of systemic tumor dormancy and metastatic progression.
引用
收藏
页码:254 / 267
页数:14
相关论文
共 50 条
  • [1] The role of FGFR1 signaling in breast cancer to induce tumor angiogenesis
    Golfmann, K.
    Meder, L.
    Schuldt, P.
    Ullrich, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 118 - 118
  • [2] FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
    Zhao, M.
    Zhuo, M-L
    Zheng, X.
    Su, X.
    Meric-Bernstam, F.
    CANCER RESEARCH, 2019, 79 (04)
  • [3] FGFR1 and EGFR Amplification in Breast Cancer
    Chen, Hui
    Singh, Rajesh
    Huo, Lei
    Lu, Xinyan
    Bousamra, Alex
    Abraham, Ronald
    Mehrotra, Meenakshi
    Mishra, Bal Mukund
    Virani, Shumaila
    Chowdhuri, Sinchita Roy
    Routbort, Mark
    Aldape, Ken
    Broaddus, Russell
    Sahin, Aysegul
    Patel, Keyur
    Luthra, Rajyalakshmi
    MODERN PATHOLOGY, 2015, 28 : 38A - 38A
  • [4] FGFR1 and EGFR Amplification in Breast Cancer
    Chen, Hui
    Singh, Rajesh
    Huo, Lei
    Lu, Xinyan
    Bousamra, Alex
    Abraham, Ronald
    Mehrotra, Meenakshi
    Mishra, Bal Mukund
    Virani, Shumaila
    Chowdhuri, Sinchita Roy
    Routbort, Mark
    Aldape, Ken
    Broaddus, Russell
    Sahin, Aysegul
    Patel, Keyur
    Luthra, Rajyalakshmi
    LABORATORY INVESTIGATION, 2015, 95 : 38A - 38A
  • [5] FGFR1 and FGF Coamplification in Breast Cancer
    Albiges, L.
    Quidville, V
    Valent, A.
    Mathieu, M. C.
    Drusch, F.
    Job, B.
    Koscielny, S.
    Delaloge, S.
    Andre, F.
    CANCER RESEARCH, 2009, 69 (24) : 762S - 763S
  • [6] Effects of FGFR1 Gene Polymorphisms on the Risk of Breast Cancer and FGFR1 Protein Expression
    Wu, Junqiang
    Wang, Yuhang
    Liu, Jing
    Chen, Qianlin
    Pang, Da
    Jiang, Yongdong
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 47 (06) : 2569 - 2578
  • [7] Significance of LIF/LIFR Signaling in the Progression of Obesity-Driven Triple-Negative Breast Cancer
    Randolph, Lois
    Joshi, Jaitri
    Sanchez, Alondra Lee Rodriguez
    Pratap, Uday P.
    Gopalam, Rahul
    Chen, Yidong
    Lai, Zhao
    Santhamma, Bindu
    Kost, Edward R.
    Nair, Hareesh B.
    Vadlamudi, Ratna K.
    Subbarayalu, Panneerdoss
    Viswanadhapalli, Suryavathi
    CANCERS, 2024, 16 (21)
  • [8] FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER plus Breast Cancer
    Gonzalez-Ericsson, Paula, I
    Servetto, Alberto
    Formisano, Luigi
    Sanchez, Violeta
    Mayer, Ingrid A.
    Arteaga, Carlos L.
    Sanders, Melinda E.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2022, 30 (09) : 600 - 608
  • [9] A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer
    Andre, F.
    Bachelot, T. D.
    Campone, M.
    Dalenc, F.
    Perez-Garcia, J. M.
    Hurvitz, S. A.
    Turner, N. C.
    Rugo, H. S.
    Shi, M. M.
    Zhang, Y.
    Kay, A. C. M.
    Yovine, A. J.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Characterization of FGFR1/2 genetic alterations reveals novel fusions of FGFR1 in Chinese breast cancer
    Wang, Y.
    Guo, L.
    Cao, L.
    Jia, M.
    Wen, L.
    Ren, C.
    Zhang, G.
    Liao, N.
    CANCER RESEARCH, 2019, 79 (04)